Market Cap ₹145 Cr.
Stock P/E 0.0
P/B 2.1
Current Price ₹73.7
Book Value ₹ 35
Face Value 10
52W High ₹145.8
Dividend Yield 0%
52W Low ₹ 55.5
Asarfi Hospital Ltd is a leading healthcare institution dedicated to providing high-quality medical services and compassionate care to its patients. With a strong commitment to excellence, the hospital offers a comprehensive range of medical specialties, cutting-edge diagnostic technology, and state-of-the-art treatment options. Asarfi Hospital Ltd prides itself on its team of skilled and experienced medical professionals who are dedicated to delivering personalized healthcare solutions. The hospital's patient-centered approach, modern facilities, and focus on continuous innovation have established it as a trusted healthcare provider in the region. Asarfi Hospital Ltd strives to improve the well-being of individuals and communities by offering advanced medical care with empathy and integrity.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|
| Net Sales | 43 | 54 | 65 | 69 | |
| Other Income | 0 | 0 | 1 | 2 | |
| Total Income | 43 | 54 | 66 | 71 | |
| Total Expenditure | 37 | 46 | 54 | 55 | |
| Operating Profit | 7 | 8 | 12 | 16 | |
| Interest | 1 | 1 | 1 | 1 | |
| Depreciation | 2 | 3 | 3 | 4 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 4 | 5 | 8 | 11 | |
| Provision for Tax | 1 | 1 | 2 | 3 | |
| Profit After Tax | 3 | 4 | 6 | 8 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 3 | 4 | 6 | 8 | |
| Adjusted Earnings Per Share | 3.5 | 4.7 | 7.6 | 5.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 6% | 17% | 0% | 0% |
| Operating Profit CAGR | 33% | 32% | 0% | 0% |
| PAT CAGR | 33% | 39% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 25% | 26% | 24% | 24% |
| ROCE Average | 26% | 27% | 26% | 26% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Shareholder's Funds | 13 | 17 | 23 | 42 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 2 | 3 | 6 | 11 |
| Other Non-Current Liabilities | 4 | 9 | 19 | 21 |
| Total Current Liabilities | 8 | 9 | 15 | 20 |
| Total Liabilities | 28 | 37 | 63 | 93 |
| Fixed Assets | 18 | 22 | 31 | 39 |
| Other Non-Current Assets | 0 | 5 | 10 | 18 |
| Total Current Assets | 9 | 10 | 22 | 37 |
| Total Assets | 28 | 37 | 63 | 93 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 2 | 10 | 9 | -2 |
| Cash Flow from Investing Activities | -5 | -16 | -23 | -14 |
| Cash Flow from Financing Activities | 2 | 6 | 14 | 17 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | 1 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 1 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.5 | 4.71 | 7.64 | 5.53 |
| CEPS(Rs) | 6.74 | 8.6 | 12.11 | 8.2 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 17.83 | 22.54 | 30.18 | 28.86 |
| Core EBITDA Margin(%) | 14.54 | 14.85 | 16.54 | 20.01 |
| EBIT Margin(%) | 9.56 | 9.98 | 12.91 | 17.77 |
| Pre Tax Margin(%) | 8.34 | 8.82 | 11.84 | 15.82 |
| PAT Margin (%) | 6.13 | 6.53 | 8.79 | 11.65 |
| Cash Profit Margin (%) | 11.78 | 11.91 | 13.92 | 17.28 |
| ROA(%) | 9.51 | 10.89 | 11.46 | 10.27 |
| ROE(%) | 19.66 | 23.36 | 28.99 | 24.87 |
| ROCE(%) | 21.8 | 25.21 | 28.88 | 26.21 |
| Receivable days | 20.05 | 15.02 | 20.79 | 59.02 |
| Inventory Days | 3.58 | 4.18 | 5.35 | 6.67 |
| Payable days | 155.74 | 34.13 | 27.09 | 67.33 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.11 | 0.03 | -0.01 | 0.34 |
| EV/Core EBITDA(x) | 0.71 | 0.2 | -0.07 | 1.44 |
| Net Sales Growth(%) | 0 | 26.25 | 20.46 | 5.56 |
| EBIT Growth(%) | 0 | 31.73 | 55.89 | 45.24 |
| PAT Growth(%) | 0 | 34.51 | 62.08 | 39.92 |
| EPS Growth(%) | 0 | 34.51 | 62.08 | -27.64 |
| Debt/Equity(x) | 0.41 | 0.42 | 0.51 | 0.41 |
| Current Ratio(x) | 1.11 | 1.12 | 1.5 | 1.86 |
| Quick Ratio(x) | 1.06 | 1.03 | 1.42 | 1.79 |
| Interest Cover(x) | 7.8 | 8.61 | 11.99 | 9.13 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Mar 2024 |
|---|---|---|
| Promoter | 61.17 | 61.17 |
| FII | 0 | 0 |
| DII | 3.25 | 2.33 |
| Public | 35.58 | 36.5 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Sep 2023 | Mar 2024 |
|---|---|---|
| Promoter | 1.2 | 1.2 |
| FII | 0 | 0 |
| DII | 0.06 | 0.05 |
| Public | 0.7 | 0.72 |
| Others | 0 | 0 |
| Total | 1.97 | 1.97 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
